BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/14/2026 5:58:20 AM | Browse: 81 | Download: 254
Publication Name World Journal of Cardiology
Manuscript ID 118879
Country United States
ISSN 1949-8462 (online)
Open Access This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cardiac & Cardiovascular Systems
Manuscript Type Meta-Analysis
Article Title Clinical outcomes of finerenone in heart failure: A systematic review and meta-analysis
Manuscript Source Invited Manuscript
All Author List Maneeth Mylavarapu, Madiha Kiyani, Andrew Ndakotsu, Vaibhav Vats, Nithin Karnan, Elizabeth Caroline Palaparthi, Mahnoor Anjum, Lakshmi Sai Meghana Kodali, Aneeza Jamshed and Fabio Enrique Parada Cabrera
ORCID
Author(s) ORCID Number
Maneeth Mylavarapu http://orcid.org/0009-0004-2367-9615
Lakshmi Sai Meghana Kodali http://orcid.org/0009-0009-2200-8234
Funding Agency and Grant Number
Corresponding Author Maneeth Mylavarapu, MD, Senior Researcher, Department of Cardiology, Endeavor Health Cardiovascular Institute, 2100 Pfingsten Rd, Glenview, IL 60026, United States, Glenview, IL 60026, United States. dr.maneeth.mylavarapu@gmail.com
Key Words Finerenone; Heart failure; Nonsteroidal mineralocorticoid receptor antagonists; Kansas City Cardiomyopathy Questionnaire; Hyperkalemia; Meta-analysis
Core Tip Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has shown clear benefits in chronic kidney disease, but its specific impact on heart failure (HF) has required further synthesis. Our meta-analysis of 7457 patients reveals that finerenone significantly decreases the odds of worsening HF and enhances quality of life scores. However, potential safety signals, including hyperkalemia, suggest that while finerenone is a potent tool for managing HF, its use requires vigilant monitoring to balance clinical benefits against adverse events.
Publish Date 2026-04-14 05:58
Citation

Mylavarapu M, Kiyani M, Ndakotsu A, Vats V, Karnan N, Palaparthi EC, Anjum M, Kodali LSM, Jamshed A, Cabrera FEP. Clinical outcomes of finerenone in heart failure: A systematic review and meta-analysis. World J Cardiol 2026; 18(4): 118879

URL https://www.wjgnet.com/1949-8462/full/v18/i4/118879.htm
DOI https://dx.doi.org/10.4330/wjc.v18.i4.118879
Full Article (PDF) WJC-18-118879-with-cover.pdf